In 1989 we carried out a trial comparing allogeneic BMT to chemotherapy (CT) in 76 children with relapsed acute lymphoblastic leukaemia (ALL). Ten years on we have clinically revised outcome to firmly establish the role of each treatment, to analyse the importance of length of first remission and to provide long-term actuarial results for disease-free survival (DFS) and relapse rate in each group. For 21 patients within the transplantation group, probability of DFS and relapse are 42.8 ± 10.8% and 40.2 ± 11.7% (s.e.), respectively. In the chemotherapy group, probability of DFS is 10.0 ± 4.74% (P = 0.001) and probability of relapse 87.5 ± 5.2% (P = 0.0004). These results strongly reflect those at initial analysis, confirming a key role of BMT in the management of ALL in second remission. Moreover, on univariate analysis only two factors influenced DFS: treatment group and length of first complete remission (less or more than 30 months from first CR). Thus, it seems clear that the best therapeutic option in early relapse is BMT, whereas DFS in late relapse is at the limit of significance (P = 0.07), with a higher relapse rate in the CT group. Although encouraging results using intensified rotational combination chemotherapy have been published, prospective randomised studies are needed to assess with certainty the best therapeutic option in these patients. Keywords: BMT vs chemotherapy; childhood ALL; second CR; revisited In 1989, we concluded that allogeneic bone marrow transplantation (BMT) is the best alternative therapy for children with ALL who have relapsed in their marrow.
In 1989, we concluded that allogeneic bone marrow transplantation (BMT) is the best alternative therapy for children with ALL who have relapsed in their marrow. 1 In that report, we prospectively studied 76 such patients, 21 of whom had a genotypically identical HLA donor and underwent allogeneic BMT. The remaining 55 patients who Correspondence: Prof A Torres, Department of Haematology, University Hospital 'Reina Sofia', Avda. Menendez Pidal s/n, 14004 Córdoba, Spain Received 22 October 1998; accepted 20 December 1998 lacked a suitable donor, received conventional chemotherapy (CT). Probability of survival was significantly higher in the BMT group (47.1 ± 11.7% vs 9.2 ± 5.6%, P Ͻ 0.025). Probability of remaining in complete remission in the BMT group was 58.5% vs 10.9% in the chemotherapy group (P Ͻ 0.005).
At the time of publication of those findings and as a consequence of the discouraging results initially obtained by some groups with BMT for ALL patients in second CR, 2, 3 many controversies arose, such as whether or not these children should undergo allogeneic BMT. [4] [5] [6] [7] In the last 10 years, despite the lack of well-designed randomised studies with large numbers of patients, all results seem to confirm that high-dose chemotherapy and bone marrow transplantation from an histocompatible donor afford a greater chance of leukaemia-free survival than does conventional chemotherapy. However, it has been recently pointed out 8 that indications for BMT in ALL are not fully established, because of publications involving small numbers of patients, difficulties over selection bias since most patients lack a suitable sibling donor, and importantly, that a very long follow-up is needed to assess results of a second course of chemotherapy.
On the other hand, it has been stated that the accuracy of actuarial results from life-table analyses are in close relationship with the size and stratification of the sample and with observation time. This latter factor is essential to obtain accurate information, since pitfalls in analysis of survival in clinical trials with a short follow-up have been published. 9, 10 We have therefore carried out a revisited analysis of our comparative ALL series (BMT vs chemotherapy) 10 years on, in order to find out if our initial results are confirmed.
Patients and methods
Seventy-six children ranging from 2 to 17 years of age, diagnosed with ALL, who relapsed in the bone marrow while undergoing conventional chemotherapy and who then re-entered remission between 1980 and 1988, were eligible for the study.
Twenty-one of the 76 patients had an HLA-identical sib-ling donor and were accepted for BMT at Reina Sofia Hospital in Cordoba, while the other 55 patients were treated with conventional chemotherapy (CT). All patients attained first complete remission as described in the original paper. Chemotherapy protocols used to effect second remission were mainly those described by Rivera et al, for treatment of ALL in first bone marrow relapse 11 and in refractory disease. 12 Transplantation conditioning regimen, number of infused nucleated bone marrow cells, acute GVHD prophylaxis, gastrointestinal decontamination, method of isolation, and antibiotic and transfusion policy, were described in the original report. 1 
Statistical analysis
The present survival analysis was carried out on 30 June 1998 with a median follow-up time from the haematological documentation of second CR of 14.54 years (range 11.08-18.47) for the whole group (13.95 and 14.55 years for the chemotherapy and transplantation group, respectively). The 2 (Yates) statistical analysis method was used to test for differences in discontinuous variables and the Student's t-test for continuous variables. The Kaplan-Meier method was used to determine life-tables for survival and relapse rates. Differences between groups were tested using the log-rank test.
Results

Comparison between bone marrow transplantation and chemotherapy group
Fifteen of the 55 patients who lacked a genotypically HLAidentical bone marrow donor were excluded from analysis because they relapsed within 3 months of achieving second complete remission.
Both groups were comparable with respect to age, sex ratio, risk factors and presence of extramedullary disease at onset and at first relapse. Length of first remission was similar in the transplant group (median 15.5 months) compared to the chemotherapy group (median 15.9 months) with no significant differences. The interval between second complete remission and BMT was 3.9 months (range 1-13 months).
Relapse rate and survival
Twelve out of 21 patients (57%) in the BMT group died, eight of relapse and disease progression despite salvage CT, three of interstitial pneumonitis (one idiopathic and two secondary to varicella zoster virus infection) and one patient developed a, presumably secondary, CNS tumour (undifferentiated glioblastoma). Median interval from relapse to death was 0.22 years (range 0.11-0.69 years). Nine patients are alive, well and disease free, with a performance (IK) of 100% from 11.30 to 16.9 years (all in the plateau phase of the survival curve). Disease-free survival (DFS) and overall survival probability is 42.8 ± 10.8% and the probability of relapse is 40.2 ± 11.7%.
In the CT group, 35 of 40 evaluable patients relapsed again. Isolated CNS relapses (three patients) attained a short third CR after CNS-directed induction treatment but eventually they died of disease progression with BM involvement. Seven patients refused further intensive CT treatments and also died. The remaining 25 were treated with standard four drug induction or salvage CT protocols, mainly the TRAMPCOL regimen, 13 with discouraging results since only four patients attained a very short third CR and all eventually died of pancytopenia, disease progression and one patient at day +1690 of multifocal leukoencephalopathy. Median interval from relapse to death was 0.46 years (range 0.02-1.05 years). None underwent an unrelated BMT. The remaining four patients are alive and disease-free from 11.08 to 18.47 years after the second complete remission. The probability of disease-free survival and overall survival is 10.0 ± 4.74%. The probability of relapse is 87.5 ± 5.2%.
On univariate analysis, only two factors influenced DFS: treatment group and length of first CR (less or more than 30 months from first CR). Concerning probability of relapse, the BMT group had a statistically significant lower relapse rate, vs CT group (see Table 1 ). According to length of first remission, we analysed separately early and late relapses: for 44 patients who relapsed earlier than 30 months from first CR, DFS is statistically better in the BMT group compared to the CT group, and probability of relapse is significantly lower. Of the 17 patients who relapsed more than 30 months after first CR, probability of relapse is also significantly favoured by BMT, and the figures for DFS are close to statistical significance (Figures 1a, b, c and d) .
Factors considered in the multivariate analysis: sex, WBC count at diagnosis, age at diagnosis, FAB subtype, Table 1 Results of univariate analysis of all considered prognostic factors length of first complete remission and treatment group (BMT or CT), and their statistical significance are shown in Table 2 .
Discussion
The results shown in our current analysis are virtually identical to those seen 10 years ago. 1 DFS and probability of remaining in complete remission in the CT and BMT groups appear as then. We therefore confirm with a longer follow-up period the superiority of BMT over CT as a therapeutic option in the treatment of children with ALL in second CR, globally considered.
In a recent review, Chessells 8 outlined the importance of the length of first remission as the main prognostic factor, and suggested a uniform definition of early and late relapse, pointing out that all trials should give detailed analysis using these criteria, especially those comparing alternative forms of high-dose therapy. With the long follow-up in our series we are able to confirm that duration of first remission (more or less than 30 months) represents an important prognostic factor which could be pivotal in establishing the therapeutic schedule for maintaining second CR. Results from other series suggested the significance of this factor as an important indicator of later therapeutic outcome, [14] [15] [16] [17] [18] and it seems clear that the best therapeutic option in early relapse is BMT. However, if published data concerning late relapses are considered, some authors such as Rivera et al 19 have reported excellent results with rotational intensive chemotherapy in 34 ALL patients (relapsed at a median of 45 months). With an EFS of 65 ± 8% and an overall survival of 79 ± 7% with a median follow-up of 9.4 years, the authors postulate that intensive chemotherapy is the treatment of choice in late relapses. Nevertheless, these data have not been reported by other groups 20, 21 and are clearly superior to those reported by Pui et al. 22 In this report, published results for DFS (31 ± 17%) were in close agreement with those from the IBMTR retrospective analysis, reported by Barrett et al 15 (32 ± 6% DFS in CT group vs 53 ± 7% in BMT group) and with results from our long follow-up prospective study. Our figures which are at the limit of statistical significance (P = 0.07) probably due to low patient numbers, are nonetheless, highly illustrative and supported by the significantly higher relapse rate in the CT group (30 ± 7% vs 66 ± 6% in the IBMTR report and 28.5 ± 17 vs 80 ± 12%, P = 0.03 in our series). Despite these superior results for BMT, intensive rotational chemotherapy schedules 19 should be appraised since they report similar or even higher rates of DFS in late relapses. Therefore, prospective randomised studies in this subset of patients are needed to assess the best therapeutic option. Chemotherapy treatment in these patients could be justified on the basis of BMT being contraindicated, individual centre facilities or clinical experience of the centre.
Patients in second CR after early relapse are, in our opinion, clear candidates for BMT if an HLA genetically identical donor is available. Also, if an HLA-identical UD (mainly bone marrow or peripheral stem cell source) is found, an UD-BMT should be offered because of the disappointing results with CT. Improvements in UD-BMT transplant-related mortality are increasingly being reported and it would be therefore be possible to randomise patients in a large trial and resolve definitively the uncertainties in the management of childhood ALL in second remission.
